A Diabetic Case Treated by Imeglimin (Twymeeg) and semaglutide (Rybelsus) With Later Development of Arteriosclerosis

Fujii F, Bando H, Kawahito A, Sueki E, Aihara A, Kanazawa S, Ikezoe M, Fukushima N and Kato Y

Published on: 2024-09-29

Abstract

The patient is 60-year-old female with type 2 diabetes (T2D) and obesity of BMI 36.8kg/m². Her HbA1c was 7.2% and weight was 84 kg in January 2022. She started to take imeglimin (Twymeeg) 2000mg/day and HbA1c value was gradually decreased to 6.4% in August 2022. She did not have apparent macroangiopathy or microangiopathy so far. Pusle wave velocity (PWV) showed ankle brachial index (ABI) 0.93/0.66, brachial-ankle PWV (baPWV) 1567/1346 cm/s, %mean artery pressure (%MAP) 54%, and upstroke time (UT) 250 ms. Consequently, peripheral artery disease (PAD) was found this time. Further evaluation and related treatment are to be initiated.